Advertisement
Canada markets open in 1 hour 27 minutes

  • S&P/TSX

    21,516.90
    -94.40 (-0.44%)
     

  • S&P 500

    5,487.03
    +13.80 (+0.25%)
     

  • DOW

    38,834.86
    +56.76 (+0.15%)
     

  • CAD/USD

    0.7293
    -0.0005 (-0.06%)
     

  • CRUDE OIL

    81.73
    +0.16 (+0.20%)
     

  • Bitcoin CAD

    90,744.20
    +1,366.34 (+1.53%)
     

  • CMC Crypto 200

    1,375.25
    -7.41 (-0.54%)
     

  • GOLD FUTURES

    2,352.00
    +5.10 (+0.22%)
     

  • RUSSELL 2000

    2,025.23
    +3.22 (+0.16%)
     

  • 10-Yr Bond

    4.2170
    0.0000 (0.00%)
     

  • NASDAQ futures

    20,017.00
    +97.75 (+0.49%)
     

  • VOLATILITY

    12.59
    +0.11 (+0.88%)
     

  • FTSE

    8,232.56
    +27.45 (+0.33%)
     

  • NIKKEI 225

    38,633.02
    +62.26 (+0.16%)
     

  • CAD/EUR

    0.6803
    +0.0016 (+0.24%)
     

Chimerix to Participate in Fireside Chat at Jefferies Global Healthcare Conference

Chimerix, Inc.
·1 min read
Chimerix, Inc.
Chimerix, Inc.

DURHAM, N.C., May 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Andriole, Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 3:00 p.m. ET.

An audio webcast of the panel discussion will be available on the Investor Relations section of Chimerix's website at ir.chimerix.com, where it will be archived for approximately 90 days.

About Chimerix
Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company’s most advanced clinical-stage development program, ONC201, is in development for H3 K27M-mutant glioma.

CONTACT:

Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com